I thought the uptick in M&A activity in the biopharma world would be interesting to post with regard to the possible future value of CYDY. I don’t know how extensive the “other experimental drugs” are, but based on the one approved drug, it is about 14 times expected annual sales.

J&J is paying $14.6B for Intra-Cellular Therapies.

Quote:

---

Johnson & Johnson said on Monday it would buy neurological drugmaker Intra-Cellular Therapies for $14.6 billion, its biggest deal in more than two years, boosting its presence in the market for brain disease treatments.

The deal would allow J&J to gain access to Intra-Cellular's oral therapy, Caplyta, which is approved in the U.S. to treat schizophrenia and depressive episodes associated with bipolar disorder, and other experimental drugs under development.

Caplyta brought in $481.3 million in sales in the first nine months of 2024 and does not face generic competition until 2040. Analysts expect the treatment to bring in more than $1 billion in sales next year, according to data compiled by LSEG.

The transaction comes on the heels of a major industry conference starting on Monday in San Francisco. Ahead of the deal's announcement, healthcare dealmakers had said they expect a resurgence of deals exceeding $10 billion due to the potential for less antitrust scrutiny under President-elect Donald Trump.

---

https://www.reuters.com/markets/deals/jj-buy-...025-01-13/